Suppr超能文献

采用多重自身抗体 ELISA 芯片提高 1 型糖尿病的诊断。

Improved diagnosis of type-1 diabetes mellitus using multiplexed autoantibodies ELISA array.

机构信息

Shenzhen Blot Biotechnology Co. Ltd, 518052, China.

Shenzhen Light Life Technology Co. Ltd, 518107, China.

出版信息

Anal Biochem. 2022 Jul 15;649:114722. doi: 10.1016/j.ab.2022.114722. Epub 2022 May 7.

Abstract

Autoantibodies are currently the most robust biomarkers of type 1 diabetes. However, single autoantibody targeted detection is still limited in diabetes diagnosis with poor performance. Here, we develop a multiplexed Array-ELISA assay that can detect five diabetes-related autoantibodies including glutamic acid decarboxylase antibody (GADA), insulinoma antigen 2 antibody (IA-2A), islet cell antibody (ICA), zinc transporter 8 autoantibody (ZnT8-A) and insulin antibody (IAA) simultaneously. This assay achieved 100% accuracy in identifying the positive and negative control samples with good repeatability (CV<15%). We applied the Array-ELISA assay to 140 clinical serum samples of healthy subjects and diabetes patients and the assay showed improved diagnosis accuracy (sensitivity of 62.5%, specificity of 94.3%) compared with the single target immunoblotting test. These data suggest that the Array-ELISA assay can provide diagnostic and predictive ability in the clinical practice of type 1 diabetes.

摘要

自身抗体目前是 1 型糖尿病最具稳健性的生物标志物。然而,单一自身抗体靶向检测在糖尿病诊断中的性能仍较差,存在局限性。在这里,我们开发了一种多重微阵列酶联免疫吸附测定(Array-ELISA)assay,可同时检测五种与糖尿病相关的自身抗体,包括谷氨酸脱羧酶抗体(GADA)、胰岛抗原 2 抗体(IA-2A)、胰岛细胞抗体(ICA)、锌转运体 8 自身抗体(ZnT8-A)和胰岛素抗体(IAA)。该 assay 在识别阳性和阴性对照样本时达到了 100%的准确率,具有良好的可重复性(CV<15%)。我们将 Array-ELISA assay 应用于 140 例健康受试者和糖尿病患者的临床血清样本,与单靶免疫印迹试验相比,该 assay 显示出了改善的诊断准确性(灵敏度为 62.5%,特异性为 94.3%)。这些数据表明,Array-ELISA assay 可在 1 型糖尿病的临床实践中提供诊断和预测能力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验